Login to Your Account

Alexion Nabs Ultra Rare Disease Candidate with $1B Enobia Buy

By Catherine Shaffer
BioWorld Today Contributing Writer

Tuesday, January 3, 2012
Alexion Pharmaceuticals Inc., of Cheshire, Conn., closed out 2011 with an impressive all-cash acquisition of Montreal-based Enobia Pharma Corp. for $610 million up front and $470 million in sales and regulatory milestones. Enobia's lead product, asfotase alfa (ENB-040), is a Phase II enzyme therapy for the ultra-orphan disease hypophosphatasia (HPP), which causes death and severe morbidity in its sufferers.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription